GILD

Gilead Sciences, Inc. Press Releases

$106.09
*  
0.58
0.54%
Get GILD Alerts
*Delayed - data as of Oct. 22, 2014  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014
10/21/2014 5:00:00 PM - Business Wire
▼-0.62 % Price Change since this news event. The Volume Ratio is 0.86.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
10/16/2014 1:30:00 PM - Business Wire
▲7.20 % Price Change since this news event. The Volume Ratio is 1.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
10/10/2014 1:54:00 PM - Business Wire
▲0.58 % Price Change since this news event. The Volume Ratio is 14.78.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Novartis drug Signifor® LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly
9/26/2014 7:18:00 AM - GlobeNewswire


European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults
9/26/2014 7:18:00 AM - Business Wire


Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies
9/24/2014 8:30:00 AM - Business Wire


Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection
9/24/2014 12:00:00 AM - Business Wire


European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
9/19/2014 6:22:00 AM - Business Wire


Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer
9/17/2014 6:00:00 AM - Business Wire


Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries
9/15/2014 6:30:00 AM - Business Wire


First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study
9/8/2014 8:45:00 AM - Business Wire


Gilead Sciences to Present at Two Upcoming Investor Conferences in September
9/3/2014 5:00:00 PM - Business Wire